<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="case-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Pathol. Oncol. Res.</journal-id>
<journal-title>Pathology &#x26; Oncology Research</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Pathol. Oncol. Res.</abbrev-journal-title>
<issn pub-type="epub">1532-2807</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1611109</article-id>
<article-id pub-id-type="doi">10.3389/pore.2023.1611109</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pathology and Oncology Archive</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A case report of recurrent leiomyosarcoma with chondrosarcoma differentiation in the abdominal wall and a review of the literature</article-title>
<alt-title alt-title-type="left-running-head">Zuo et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/pore.2023.1611109">10.3389/pore.2023.1611109</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zuo</surname>
<given-names>Xuan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Wei L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Peng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Tian M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Na</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2197482/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Pathology</institution>, <institution>West China Second University Hospital</institution>, <institution>Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Key Laboratory of Birth Defects and Related Diseases of Women and Children</institution>, <institution>Ministry of Education</institution>, <institution>Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1002509/overview">Kren&#xe1;cs Tibor</ext-link>, Semmelweis University, Hungary</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Lei Li, <email>lipath@163.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>05</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>29</volume>
<elocation-id>1611109</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>02</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>04</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Zuo, Wu, Shi, Liu, Yu and Li.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zuo, Wu, Shi, Liu, Yu and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Leiomyosarcoma with heterologous differentiation is relatively rare. To date, only 19 cases have been reported in the English literature. Heterologous components frequently show histological pleomorphism, while those exhibiting well-differentiated morphology are seldom reported. Here, we report a 34-year-old female diagnosed with leiomyosarcoma and developed abdominal wall recurrence 8&#xa0;years after primary surgery. The recurrent tumor mainly comprised well-differentiated chondrosarcoma except a single focus of leiomyosarcoma. Due to the rarity and prolonged onset of such a transition, our case provides insight into the understanding of this phenomenon.</p>
</abstract>
<kwd-group>
<kwd>recurrence</kwd>
<kwd>case report</kwd>
<kwd>leiomyosarcoma</kwd>
<kwd>heterologous differentiation</kwd>
<kwd>chondrosarcoma</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Case report</title>
<p>A 34-year-old woman presented to our hospital with concerns of an abdominal mass with dull pain for several days. Physical examination found a palpable mass measuring 5&#x2013;6&#xa0;cm in diameter in the lower abdomen. Computed tomography revealed a multinodular mass measuring 7.6&#xa0;cm &#xd7; 4.1&#xa0;cm &#xd7; 6.5&#xa0;cm located in the rectus abdominis muscle with multifocal calcification and uneven enhancement. Serum tumor markers such as CA125 (Cancer Antigen 125), SCC (Squamous Cell Carcinoma Antigen), and CA19-9 (Cancer Antigen 19-9) were all in the normal range. She had a history of &#x201c;broad ligament leiomyosarcoma&#x201d; 8&#xa0;years prior and was treated with radical resection in our hospital. Because recurrence was suspected, she underwent a second surgery for abdominal mass excision. A tough and irregular mass was found beneath the lower abdominal wall during the operation. The mass invaded the subcutaneous fat layer and penetrated through the rectus abdominis muscle. No other intraoperative abnormities were found.</p>
<p>Grossly, the tumor had a multinodular appearance in the abdominal muscles below the superficial fascia and intruded into the extraperitoneal adipose tissue. Nodules measuring from 4 to 9&#xa0;cm were found isolated from each other. All nodules were irregular in shape, with sharp margins and well-demarcated outlines. The cut surfaces were all cartilage-like with a brittle texture, gray to gray&#x2012;white color and focal calcification (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Cartilage-like cut surface of the abdominal wall mass.</p>
</caption>
<graphic xlink:href="pore-29-1611109-g001.tif"/>
</fig>
<p>Microscopically, the vast majority of the neoplasm was composed of well-differentiated cartilaginous islands arranged in lobules (<xref ref-type="fig" rid="F2">Figure 2A</xref>). The boundaries were generally smooth. The chondrocytes were uniform in shape with mild to moderate atypia and were unevenly distributed in the cartilage matrix (<xref ref-type="fig" rid="F2">Figures 2B, C</xref>). Aside from the cartilage islands, a single cluster of spindle cells was observed (<xref ref-type="fig" rid="F2">Figure 2D</xref>). The spindle cells were arranged in bundles and featured cigar-shaped nuclei and eosinophilic cytoplasm (<xref ref-type="fig" rid="F2">Figure 2E</xref>). The spindle cells were positive for ER (Estrogen Receptor), PR (Progesterone Receptor), Caldesmon and Desmin, indicating an origin of smooth muscle cells from the genital tract. The strong positivity of P53 in chondrocytes indicated that cartilage islands, although well differentiated, were malignant (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The microscopic characteristics and immunochemical phenotype of the recurrent tumor. <bold>(A)</bold> Cartilage islands were arranged in nodules. <bold>(B)</bold> Chondrocytes were well differentiated with mild to moderate atypia. <bold>(C)</bold> A chondrocyte with bizarre nuclei (indicated by the yellow arrow). <bold>(D)</bold> A bundle of spindle cells was observed next to the cartilage island (indicated by the blue arrow). <bold>(E)</bold> The nucleus of the spindle cell was cigar shaped [Hematoxylin-eosin staining; Magnification: <bold>(A,D)</bold> &#xd7;40, <bold>(B&#x2013;D)</bold> &#xd7;200; Immunochemistry staining; Magnification: &#xd7;200].</p>
</caption>
<graphic xlink:href="pore-29-1611109-g002.tif"/>
</fig>
<p>To clarify the relationship between recurrent and primary tumors, we reviewed the histomorphology of the former surgical specimen. The primary tumor was composed of two types of cells: spindle cells and epithelioid cells. Sarcomatoid-like spindle cells were arranged in the fasciculus or vortex with cigar-shaped nuclei and sparse eosinophilic cytoplasm under high magnification (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Epithelioid cells with round to ovoid nuclei and prominent nucleoli arranged in cords or small nests were embedded in the edematous and mucinous matrix (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Marked necrosis could be easily observed under low-power microscopy (<xref ref-type="fig" rid="F3">Figure 3C</xref>). The tumor cells showed overall mild to moderate atypia with active mitosis demonstrating over 10/10 HPF (<xref ref-type="fig" rid="F3">Figures 3D, E</xref>). Such morphological characteristics met the standard for a diagnosis of leiomyosarcoma. It is worth mentioning that no heterologous component was discovered after thorough evaluation.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Microscopic characteristics and immunophenotypes of the primary tumor. <bold>(A)</bold> Spindle cells with cigar-shaped nuclei were arranged in a fascicular pattern. <bold>(B)</bold> Epithelioid cells with mild to moderate atypia were lined in a lace-like pattern. <bold>(C)</bold> Coagulative necrosis was frequently seen. <bold>(D)</bold> Mitoses were easily observed. <bold>(E)</bold> Tumor cells exhibited mild to moderate atypia [Hematoxylin-eosin staining: <bold>(A)</bold> &#xd7;200. <bold>(</bold>B<bold>)</bold> &#xd7;100. <bold>(C)</bold> &#xd7;40. <bold>(</bold>D,<bold>E)</bold> &#xd7;400. Immunochemistry staining: &#xd7;400].</p>
</caption>
<graphic xlink:href="pore-29-1611109-g003.tif"/>
</fig>
<p>The final diagnosis was leiomyosarcoma with epithelioid differentiation. The patient then received 4 cycles of APDTIC (EPB, DTIC, DDP) chemotherapy after radical surgery.</p>
<p>The immunoprofiles of primary and recurrent tumor were listed in <xref ref-type="table" rid="T1">Table 1</xref>. As shown below, tumor cells in both lesions were positive for Vimentin, ER, PR, Caldesmon, SMA (Smooth Muscle Actin), Desmin, and negative for P-CK (pan Cytokeratin). P16 was found patchy in both lesions. The Ki67 index was approximately 25% in the primary neoplasm. Although it was only 2% in the recurrent neoplasm, the increased expression of P53 indicated malignant biological behavior of the recurrent tumor.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The immunophenotypes of primary and recurrent leiomyosarcoma.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Lesion</th>
<th align="left">Vimentin</th>
<th align="left">P-CK</th>
<th align="left">Desmin</th>
<th align="left">SMA</th>
<th align="left">Caldesmon</th>
<th align="left">ER</th>
<th align="left">PR</th>
<th align="left">P53</th>
<th align="left">P16</th>
<th align="left">Ki67 (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Primary lesion</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2013;</td>
<td align="left">MF&#x2b;</td>
<td align="left">MF&#x2b;</td>
<td align="left">&#x2b;&#x2b;</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2b;&#x2b;</td>
<td align="left">Single&#x2b;</td>
<td align="left">F&#x2b;</td>
<td align="left">35</td>
</tr>
<tr>
<td align="left">Recurrent lesion</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2013;</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2b;&#x2b;&#x2b;</td>
<td align="left">&#x2b;&#x2b;</td>
<td align="left">F&#x2b;</td>
<td align="left">&#x2b;</td>
<td align="left">F&#x2b;</td>
<td align="left">2</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Abbreviations: &#x2b;, weak positive; &#x2b;&#x2b;, moderate positive; &#x2b;&#x2b;&#x2b;, strong positive; &#x2013;, negative; F, focal; MF, multifocal.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Taking into account both the overall medical history and the histopathological characteristics, the abdominal lesion was confirmed to be leiomyosarcoma with chondrosarcoma differentiation. The patient was in good condition after 6 cycles of combined chemotherapy (pharmorubicin, cis-platinum and dacarbazine).</p>
</sec>
<sec sec-type="discussion" id="s2">
<title>Discussion</title>
<p>Although leiomyosarcoma is the most common malignant mesenchymal tumor of the uterus, such lesions containing heterologous components are rare, with fewer than 20 cases reported to date (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). The clinicopathological characteristics are summarized in <xref ref-type="table" rid="T2">Table 2</xref>. These tumors mainly affect postmenopausal women. The age of onset is reported to range from 41 to 80&#xa0;years, with an average age of 53&#xa0;years. Most patients present with an abdominal mass accompanied by dull pain or vaginal bleeding and irregular menstrual cycles. Most tumors are lobular or nodular, with a median size exceeding 15&#xa0;cm in diameter (<xref ref-type="bibr" rid="B4">4</xref>). The appearance of the cut surface depends on the property and proportion of the heterologous components. Necrosis and hemorrhage are common. These tumors display highly malignant clinical courses and can show remote recurrences (<xref ref-type="bibr" rid="B10">10</xref>). Almost all patients experience metastasis or local recurrences (16/19). Lung is the most common recurrence site. The relapse interval varies from 5&#xa0;months to 9&#xa0;years. Pathologically, heterologous components can be seen not only in primary lesions but also in metastases. Osteosarcomatous differentiation is most frequent. Most of the heterologous components are poorly differentiated. Notably, such transitions occur mainly in typical leiomyosarcoma, except for one report of a myxoid leiomyosarcoma (<xref ref-type="bibr" rid="B1">1</xref>). Whether these changes could occur in pure epithelioid leiomyosarcoma has not yet been reported.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Clinicopathological features of uterine leiomyosarcoma with heterogenous differentiation.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Case</th>
<th align="left">Age</th>
<th align="left">Treatment</th>
<th align="left">Heterologous component</th>
<th align="left">Metastasis/recurrence</th>
<th align="left">Interval before metastasis/recurrence</th>
<th align="left">Prognosis</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="left">42</td>
<td align="left">S&#x2b;RA</td>
<td align="left">Chondrosarcoma</td>
<td align="left">Right rectus muscle</td>
<td align="left">3&#xa0;years</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">45</td>
<td align="left">S</td>
<td align="left">Liposarcoma</td>
<td align="left">Spinal column</td>
<td align="left">6&#xa0;months</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">3</td>
<td align="left">53</td>
<td align="left">S</td>
<td align="left">Osteosarcoma</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">AWD</td>
</tr>
<tr>
<td align="left">4</td>
<td align="left">54</td>
<td align="left">S&#x2b;RA</td>
<td align="left">Liposarcoma, osteosarcoma, chondrosarcoma</td>
<td align="left">Mesentery</td>
<td align="left">8&#xa0;months</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">5</td>
<td align="left">50</td>
<td align="left">S</td>
<td align="left">Liposarcoma</td>
<td align="left">Lung, Pelvic cavity</td>
<td align="left">5&#xa0;months</td>
<td align="left">AWD</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">55</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Liposarcoma</td>
<td align="left">Pelvic cavity</td>
<td align="left">1&#xa0;year</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">80</td>
<td align="left">RA&#x2b;CT</td>
<td align="left">Osteosarcoma, chondrosarcoma, liposarcoma-like area</td>
<td align="left">Lung</td>
<td align="left">11&#xa0;months</td>
<td align="left"/>
</tr>
<tr>
<td align="left">8</td>
<td align="left">67</td>
<td align="left">SH</td>
<td align="left">Rhabdomyosarcoma</td>
<td align="left">Femur, abductor magnus, lymph node</td>
<td align="left">9&#xa0;years</td>
<td align="left">AWD</td>
</tr>
<tr>
<td align="left">9</td>
<td align="left">41</td>
<td align="left">M&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Lung</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">63</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Lung, diaphragm, atrium, SVC, kidney</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">40</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Colon, retroperitoneum</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">48</td>
<td align="left">S&#x2b;CT&#x2b;RA</td>
<td align="left">Osteosarcoma</td>
<td align="left">Lung, liver, peritoneum, colon, small bowel</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">55</td>
<td align="left">CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Pancreas, bone, lung</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">52</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Lung, abdomen</td>
<td align="left">NA</td>
<td align="left">AWD</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">61</td>
<td align="left">S&#x2b;CT&#x2b;RA</td>
<td align="left">Osteosarcoma</td>
<td align="left">Lung, pleura</td>
<td align="left">NA</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">53</td>
<td align="left">S</td>
<td align="left">Osteosarcoma</td>
<td align="left">&#x2014;</td>
<td align="left">&#x2014;</td>
<td align="left">DOD</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">62</td>
<td align="left">NA</td>
<td align="left">Osteosarcoma</td>
<td align="left">NA</td>
<td align="left">NA</td>
<td align="left">NA</td>
</tr>
<tr>
<td align="left">18</td>
<td align="left">43</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Small bowel</td>
<td align="left">NA</td>
<td align="left">AWD</td>
</tr>
<tr>
<td align="left">19</td>
<td align="left">52</td>
<td align="left">S&#x2b;CT</td>
<td align="left">Osteosarcoma</td>
<td align="left">Liver, small bowel</td>
<td align="left">NA</td>
<td align="left">AWD</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Abbreviations: S, surgery; RA, radiation; CT, chemotherapy; SVC, superior vena cava; NA, not available; AWD, alive with disease; DOD, died of disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In our case, the patient was initially diagnosed with leiomyosarcoma with epithelioid differentiation and experienced distant recurrence. The recurrent tumor was composed mainly of well-differentiated chondrosarcoma. Misdiagnosis can easily occur regardless of the immunotype and the patient&#x2019;s medical history. The differential diagnosis mainly depends on the proportion and histologic type of the heterologous component. Cases in which chondrosarcoma and osteosarcoma are the major components, careful sampling and detailed observations are mandatory to discover the smooth muscle component. For leiomyosarcoma with liposarcoma differentiation, the differential diagnosis from dedifferentiated liposarcoma might be challenging. In such cases, molecular tests can provide helpful evidence, as liposarcoma is characterized by the amplification of <italic>MDM2</italic> (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). When two or more unrelated differentiated histology types are confirmed in a single entity, malignant mesenchymoma should be considered (<xref ref-type="bibr" rid="B13">13</xref>). However, as most cases can be reclassified, the nomenclature is no longer applied. It is worth noting that sometimes heterologous components may be well differentiated and even mask the nature of the neoplasm. For this reason, a thorough review of the clinical information, careful sampling and skillful pathological examinations are imperative for diagnosis. The overall disease course tends to be aggressive, regardless of the histologic type and the degree of differentiation. More importantly, such tumors respond poorly to combination therapies and could develop late metastases. The mechanism underlying the development of heterologous components is likely to be the reacquisition of stem cell features and the triggering of mesenchymal primordium differentiation (<xref ref-type="bibr" rid="B14">14</xref>). An accumulation of similar cases may allow for additional in-depth studies to provide a basis for investigating pathogenetic mechanisms and biological behavior.</p>
<p>The remote metastasis that occurred in our case, although after a long remission interval, urges us to pay sufficient attention to patients who are clinically stable. Regardless the proportion of the heterologous components, the diagnosis of a <italic>de novo</italic> malignancy can only be established if recurrence is completely excluded.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s3">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s4">
<title>Ethics statement</title>
<p>This report was written in accordance with the provisions of the Declaration of Helsinki 2008 and was approved by the ethics Committee of West China Second University Hospital. Written consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s5">
<title>Author contributions</title>
<p>XZ wrote the main manuscript text. WW provided a preliminary assessment for the diagnosis. PS was responsible for the coordination between co-authors. TL and NY performed immunochemistry and provided the HE slides for observations. LL provided writing guides and reviewed the article.</p>
</sec>
<sec sec-type="COI-statement" id="s6">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thiryayi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Turashvili</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Latta</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Antonescu</surname>
<given-names>CR</given-names>
</name>
<etal/>
</person-group> <article-title>PLAG1-rearrangment in a uterine leiomyosarcoma with myxoid stroma and heterologous differentiation</article-title>. <source>Genes Chromosomes Cancer</source> (<year>2021</year>) <volume>60</volume>(<issue>10</issue>):<fpage>713</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/gcc.22980</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bapat</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brustein</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Uterine sarcoma with liposarcomatous differentiation: Report of a case and review of the literature</article-title>. <source>Int J Gynaecol Obstet</source> (<year>1989</year>) <volume>28</volume>(<issue>1</issue>):<fpage>71</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0020-7292(89)90547-x</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damjanov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Chondrosarcomatous differentiation of a metastatic leiomyosarcoma of the uterus</article-title>. <source>Virchows Arch</source> (<year>2006</year>) <volume>449</volume>(<issue>4</issue>):<fpage>493</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s00428-006-0283-5</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hornick</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>"Malignant mesenchymoma" revisited: A clinicopathologic study of leiomyosarcomas with osteosarcomatous differentiation</article-title>. <source>Am J Surg Pathol</source> (<year>2022</year>) <volume>46</volume>(<issue>10</issue>):<fpage>1430</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/PAS.0000000000001928</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maheshwari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rekhi</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Two uncommon cases of uterine leiomyosarcomas displaying heterologous osteosarcomatous de-differentiation</article-title>. <source>J Cancer Res Ther</source> (<year>2015</year>) <volume>11</volume>(<issue>3</issue>):<fpage>654</fpage>. <pub-id pub-id-type="doi">10.4103/0973-1482.140984</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cappuccini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tewari</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fuller</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Pindur</surname>
<given-names>A</given-names>
</name>
<name>
<surname>DiSaia</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Aggressive clinical behavior of a rare uterine sarcoma</article-title>. <source>Gynecol Oncol</source> (<year>1998</year>) <volume>70</volume>(<issue>1</issue>):<fpage>147</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1006/gyno.1998.5020</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyraz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gogakos</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Raskin</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>GP</given-names>
</name>
</person-group>. <article-title>Metastatic uterine leiomyosarcoma with rhabdomyosarcomatous heterologous differentiation</article-title>. <source>Int J Gynecol Pathol</source> (<year>2022</year>) <volume>42</volume>:<fpage>151</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/PGP.0000000000000874</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anh Tran</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>Metastatic leiomyosarcoma of the uterus with heterologous differentiation to malignant mesenchymoma</article-title>. <source>Int J Gynecol Pathol</source> (<year>2012</year>) <volume>31</volume>(<issue>5</issue>):<fpage>453</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/PGP.0b013e318246977d</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Den Bakker</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hegt</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Sleddens</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Nuijten</surname>
<given-names>ASM</given-names>
</name>
<name>
<surname>Dinjens</surname>
<given-names>WNM</given-names>
</name>
</person-group>. <article-title>Malignant mesenchymoma of the uterus, arising in a leiomyoma</article-title>. <source>Histopathology</source> (<year>2002</year>) <volume>40</volume>(<issue>1</issue>):<fpage>65</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2559.2002.01290.x</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Setia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kanotra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bhavthankar</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Epithelioid leiomyosarcoma of uterus [J]</article-title>. <source>BMJ Case Rep</source> (<year>2012</year>) <volume>2012</volume>:<fpage>bcr1120115144</fpage>. <pub-id pub-id-type="doi">10.1136/bcr.11.2011.5144</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thway</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Noujaim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zaidi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miah</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Dedifferentiated liposarcoma: Updates on morphology, genetics, and therapeutic strategies</article-title>. <source>Adv Anat Pathol</source> (<year>2016</year>) <volume>23</volume>(<issue>1</issue>):<fpage>30</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1097/PAP.0000000000000101</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>ATJ</given-names>
</name>
<name>
<surname>Thway</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Clinical and molecular spectrum of liposarcoma</article-title>. <source>J Clin Oncol</source> (<year>2018</year>) <volume>36</volume>(<issue>2</issue>):<fpage>151</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2017.74.9598</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stout</surname>
<given-names>AP</given-names>
</name>
</person-group>. <article-title>Mesenchymoma, the mixed tumor of mesenchymal derivatives</article-title>. <source>Ann Surg</source> (<year>1948</year>) <volume>127</volume>(<issue>2</issue>):<fpage>278</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1097/00000658-194802000-00007</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buonomo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bussolaro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giorda</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Biffi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Cotyledonoid leiomyoma clinical characteristics, imaging features, and review of the literature</article-title>. <source>J Ultrasound Med</source> (<year>2021</year>) <volume>40</volume>(<issue>7</issue>):<fpage>1459</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/jum.15510</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>